Compare Eos Energy Enterprises Inc (EOSE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs ResMed Inc. — how do they compare? Eos Energy Enterprises Inc trades at $2.52 (market cap $1.01B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 31.6× Eos Energy Enterprises Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and ResMed Inc. for 51 Days on average.
| EOSE | RMD | |
|---|---|---|
Market Cap | $1.01B | $31.89B |
Volume | 39,626,541 | 618,314 |
Sector | Industrials | Health |
52-Week High | $19.19 | $277.88 |
52-Week Low | $2.77 | $182.82 |
Typical Hold Time | 16 Days | 51 Days |
Enterprise Value | $1.34B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.52, down 18.71% in the last session, reflecting volatile sentiment despite strong revenue growth projections. The stock shows bearish technical signals with oversold RSI readings, while fundamentally the company faces significant losses with a -246.76% net income margin despite 2026 revenue doubling to $214 million. Recent positive developments include an $87 million DOE loan advance and a major Google partnership announced September 2, 2026.
While analyst consensus suggests substantial upside with a $7.10 price target, EOSE carries high risk due to persistent negative cash flow and profitability challenges. The company's zinc-based energy storage technology shows promise in a growing market, but execution risk remains elevated as scaling continues. Investors should weigh the growth potential against the company's current financial instability.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
